Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Licenses Lupus Nephritis Biomarkers From Johns Hopkins University

NEW YORK – Autoimmune test developer Exagen announced on Thursday that it will acquire a worldwide exclusive license to novel patented biomarkers for the therapeutic management of lupus nephritis from Johns Hopkins University. 

The San Diego-based company intends to develop the biomarkers into tests to help with diagnostic and treatment decisions by "providing unique clinical insight into a specific patient's lupus nephritis in a non-invasive manner," it said in a statement. 

The firm currently offers its flagship Avise CTD test, which is designed to help diagnosis systemic lupus erythematosus. It also provides tests for other diseases including antiphospholipid syndrome, vasculitis, and rheumatoid arthritis.